TY - JOUR T1 - Validating atlas-based lesion disconnectomics in multiple sclerosis: a retrospective multi-centric study JF - medRxiv DO - 10.1101/2021.05.03.21256161 SP - 2021.05.03.21256161 AU - Veronica Ravano AU - Michaela Andelova AU - Mário João Fartaria AU - Mazen Fouad A-Wali Mahdi AU - Bénédicte Maréchal AU - Reto Meuli AU - Tomas Uher AU - Jan Krasensky AU - Manuela Vaneckova AU - Dana Horakova AU - Tobias Kober AU - Jonas Richiardi Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/02/2021.05.03.21256161.abstract N2 - The translational potential of MR-based connectivity modelling is limited by the need for advanced diffusion imaging, which is not part of clinical protocols for many diseases. In addition, where diffusion data is available, brain connectivity analyses rely on tractography algorithms which imply two major limitations. First, tracking algorithms are known to be sensitive to the presence of white matter lesions and therefore leading to interpretation pitfalls and poor inter-subject comparability in clinical applications such as multiple sclerosis. Second, tractography quality is highly dependent on the acquisition parameters of diffusion sequences, leading to a trade-off between acquisition time and tractography precision.Here, we propose an atlas-based approach to study the interplay between structural disconnectivity and lesions without requiring individual diffusion imaging. In a multi-centric setting involving three distinct multiple sclerosis datasets (containing both 1.5T and 3T data), we compare our atlas-based structural disconnectome computation pipeline to disconnectomes extracted from individual tractography and explore its clinical utility for reducing the gap between radiological findings and clinical symptoms in multiple sclerosis. Results using topological graph properties showed that overall, our atlas-based disconnectomes were suitable approximations of individual disconnectomes from diffusion imaging. Small-worldness was found to decrease for larger total lesion volumes thereby suggesting a loss of efficiency in brain connectivity of MS patients. Finally, the global efficiency of the created brain graph, combined with total lesion volume, allowed to stratify patients into subgroups with different clinical scores in all three cohorts.Competing Interest StatementVeronica Ravano: Pending Patent Application; Michaela Andelova: received financial support for conference travel from Novartis, Genzyme, Merck Serono, Biogen Idec and Roche; Mario Joao Fartaria: Employee of Siemens Healthcare AG; Benedicte Marechal: Employee of Siemens Healthcare AG; Tomas Uher: received financial support for conference travel and honoraria from Biogen Idec, Novartis, Roche, Genzyme and Merck Serono, as well as support for research activities from Biogen Idec and Sanofi (GZ-2017-11718); Jan Krasensky: received financial support for research activities from Biogen Idec; Manuela Vaneckova: was supported by Czech Ministry of Health, grant RVO-VFN 64165, NV18-04-00168. She received compensation for speaker honoraria, travel and consultant fees from Biogen, Sanofi Genzyme, Novartis, Roche and Teva, as well as support for research activities from Biogen. Dana Horakova: received compensation for travel, speaker honoraria and consultant fees from Biogen, Novartis, Merck, Bayer, Sanofi, Roche, and Teva, as well as support for research activities from Biogen. She was also supported by the Czech Ministry of Education project Progress Q27/LF1. Jonas Richiardi: Pending Patent Application; Tobias Kober: Employee of Siemens Healthcare AG and Pending Patent Application. The other authors have nothing to disclose.Funding Statement1.5T cohort: SET study; Contract grant sponsor: the Ministries of Health and Education, Czech Republic; EudraCT number: 2005-001281-13; NCT number: NCT01592474; Contract grant numbers: RVO 64165/2012, MSM0021620849; PRVOUK-P26/LF1/4; 3T cohort: Spinal Cord Grant (SCG); Contract grant sponsor: the Ministry of Health, Czech Republic; Contract grant numbers: NV18-04-00168, RVO 64165; Diffusion cohort: Swiss National Science Foundation; Contract grant number: PZ00P3_131914/11; Contract grant sponsor: Centre de Imagerie Bio-Medicale (CIBM) of the University of Lausanne (UNIL); Contract grant sponsor: Centre Hospitalier Universitaire Vaudois (CHUV). The funding sources had no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report or in the decision to submit the paper for publication. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Diffusion cohort: All patients provided written informed consent, and the study was approved by the ethics committee of the State of Vaud, Switzerland. 1.5T cohort: This study was approved by the Medical Ethics Committees of the General University Hospital and First Faculty of Medicine, Charles University in Prague, and by local medical ethics committees in all participating centres. 3T cohort: The study was approved by the Ethics Committee of the General University Hospital in Prague, Czech Republic. All participants in the 1.5T and the 3T cohorts agreed with collecting and retrospectively analyzing their clinical, immunological and MRI data within an international, online registry and platform for collecting prospective data on patients with MS (MSBase) (Butzkueven et al., 2006), and within the Czech national registry of MS patients (ReMuS).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDue to patient privacy, the clinical data used in this study cannot be made openly available. ER -